AB-NK064-2P VEGFR3 Antibody

Pan-specific polyclonal antibody for monitoring the expression of human protein-tyrosine kinase VEGFR3 (Flt4)



Email: info@kinexus.ca Phone: 604-323-2547

Address: 8755 Ash Street, Suite 1 Vancouver, British Columbia, Canada V6P 6T3

Target Protein	
Name Long:	Vascular endothelial growth factor receptor 3 ; Vascular endothelial growth factor
Alias:	receptor-protein-tyrosine kinase 3 Fms-related tyrosine kinase 4; PCL; Tyrosine-protein kinase receptor FLT4; FLT41; VEGFR3; VGFR3; VGR3; CCDS4457.1; ENSG00000037280
UniProt ID:	P35916
Sequence Predicted Mass (KDa):	152.757 (1363 AA; P35916); 145.599 (1298 AA; P35916-1); 93.174 (830 AA; P35916-3)
Observed SDS-PAGE Mass (KDa):	160-175
Immunogen	
Antibody Immunogen Source:	Human VEGFR3 (Flt4) sequence peptide Cat. No.: PE-01AVP95
Antibody Immunogen Sequence:	CNELYDIQLLPRKSLE
Location in Target:	Corresponds to amino acid residues N227 to E241
Peptide Type:	For pan-specific recognition of target expression levels.
Target Phosphosite:	Not phosphorylated
Production	
Antibody Host Species:	Rabbit
Antibody Host Species: Antibody Type:	Rabbit Polyclonal
	Polyclonal Immunoglobulin G
Antibody Type:	Polyclonal
Antibody Type: Antibody Ig Isotype Clone Lot:	Polyclonal Immunoglobulin G The immunizing peptide was produced by solid phase synthesis on a multipep peptide synthesizer and purified by reverse-phase hplc chromatography. Purity was assessed by analytical hplc and the amino acid sequence confirmed by mass spectrometry analysis. This peptide was coupled to KLH prior to immunization into rabbits. New Zealand White rabbits were subcutaneously injected with KLH-coupled immunizing peptide every 4 weeks for 4 months. The sera from each animal was applied onto an agarose column to which the immunogen peptide was thio-linked. Antibody was eluted from the column with 0.1 M glycine, pH 2.5. Subsequently, the antibody solution was neutralized to pH
Antibody Type: Antibody Ig Isotype Clone Lot: Production Method:	Polyclonal Immunoglobulin G The immunizing peptide was produced by solid phase synthesis on a multipep peptide synthesizer and purified by reverse-phase hplc chromatography. Purity was assessed by analytical hplc and the amino acid sequence confirmed by mass spectrometry analysis. This peptide was coupled to KLH prior to immunization into rabbits. New Zealand White rabbits were subcutaneously injected with KLH-coupled immunizing peptide every 4 weeks for 4 months. The sera from each animal was applied onto an agarose column to which the immunogen peptide was thio-linked. Antibody was eluted from the column with 0.1 M glycine, pH 2.5. Subsequently, the antibody solution was neutralized to pH 7.0 with saturated Tris.
Antibody Type: Antibody Ig Isotype Clone Lot: Production Method: Antibody Amount:	Polyclonal Immunoglobulin G The immunizing peptide was produced by solid phase synthesis on a multipep peptide synthesizer and purified by reverse-phase hplc chromatography. Purity was assessed by analytical hplc and the amino acid sequence confirmed by mass spectrometry analysis. This peptide was coupled to KLH prior to immunization into rabbits. New Zealand White rabbits were subcutaneously injected with KLH-coupled immunizing peptide every 4 weeks for 4 months. The sera from each animal was applied onto an agarose column to which the immunogen peptide was thio-linked. Antibody was eluted from the column with 0.1 M glycine, pH 2.5. Subsequently, the antibody solution was neutralized to pH 7.0 with saturated Tris. 25 μg
Antibody Type: Antibody Ig Isotype Clone Lot: Production Method: Antibody Amount: Antibody Concentration:	Polyclonal Immunoglobulin G The immunizing peptide was produced by solid phase synthesis on a multipep peptide synthesizer and purified by reverse-phase hplc chromatography. Purity was assessed by analytical hplc and the amino acid sequence confirmed by mass spectrometry analysis. This peptide was coupled to KLH prior to immunization into rabbits. New Zealand White rabbits were subcutaneously injected with KLH-coupled immunizing peptide every 4 weeks for 4 months. The sera from each animal was applied onto an agarose column to which the immunogen peptide was thio-linked. Antibody was eluted from the column with 0.1 M glycine, pH 2.5. Subsequently, the antibody solution was neutralized to pH 7.0 with saturated Tris. 25 μg 1 mg/ml

AB-NK064-2P VEGFR3 Antibody



Address: 8755 Ash Street, Suite 1 Vancouver, British Columbia, Canada V6P 6T3

Email: info@kinexus.ca Phone: 604-323-2547

Applications	
Product Use:	Western blotting Antibody microarrays
Antibody Dilution Recommended:	2 µg/ml for immunoblotting
Antibody Species Reactivity:	Human, mouse, rat and many other mammals
Antibody Positive Controls:	Very strong immunoreactivity with recombinant human VEGFR3 on protein dot blots.
Overall Antibody Specificity:	Very high selectivity
Antibody Cross Reactivities:	Weak immunoreactivity on protein dot blots with recombinant human VGFR1 and no immunoreactivity with recombinant human VGFR2.

This product is for in vitro research use only and is not intended for use in humans or animals.